# Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

> **NCT01262352** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 21 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ivacaftor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01262352
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262352, "Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01262352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*